View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.
Breaking New Ground in Heart Failure Treatment Agenda
Introduction & Pre CME Questions Yehuda Handelsman, MD
Prevalence, Pathophysiology and Morbidities of Heart Failure Matthew J. Budoff, MD
Contemporary Approach to Management of Heart Failure Stephen J. Greene, MD
Sotagliflozin: The Next Generation of Heart Failure Management Darren McGuire, MD, MHSc
Panel Discussion, Q&A, and Post-CME: Advancing the Care of Heart Failure- Relationship to CKD Panel: Matthew J. Budoff, MD, Stephen J. Greene, MD, Darren McGuire, MD, MHSc,
Matthew R. Weir, MD Moderator: Yehuda Handelsman, MD
Faculty
Matthew J. Budoff, MD, Chair
ACC, FAHA
Professor of Medicine
David Geffen School of Medicine at UCLA
Endowed Chair of Preventive Cardiology
Program Director, Director of Cardiac CT
Lundquist Institute
Harbor-UCLA Medical Center, Division of Cardiology
Los Angeles, California
Chair & Program Director, WCIRDC
Medical Director & Principal Investigator,
Metabolic Institute of America
Chair & Founder,
International Committee for Insulin Resistance
Chair & Founder, International Lipid Forum
Tarzana, California
Matthew R. Weir, MD
Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland
Stephen J. Greene, MD
Assistant Professor, Division of Cardiology
Advanced Heart Failure & Transplantation
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina
Darren McGuire, MD, MHSc
Distinguished Teaching Professor of Medicine with Tenure
Program Description
This CME satellite symposium will explore the changing landscape of therapies for patients with HF with or without diabetes. The program will address the gaps in physicians’ knowledge of the Epidemiology & and pathophysiology of heart failure, the new 2022 ACC/AHA/HFSA Ejection Fraction based Heart Failure management guidelines, and the emerging role of sotagliflozin an SGLT2/1- in heart Failure patients with and without T2D, CKD and other CV risks.
Learning Objectives
Upon completion of this CME symposium, participants should be able to:
Discuss the epidemiology of HF
Understand the Pathophysiology of HF
Be Aware of the Ejection Fraction based 2022 treatment Guidelines for HF
Describe the Potential Mode of action of SGLT2 & SGLT1 inhibitors.
Develop management strategies for patients with HF including those with DM & CKD
Target Audience
This educational initiative is designed for cardiologists, endocrinologists, nephrologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of people with Heart failure or Type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
CME Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PES Inc. is accredited by the ACCME to provide continuing medical education for physicians.
PESI, Inc, designated this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s).
Physicians should only claim credit commensurate with the extent of their participation in the activity.
